A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

• Safety and tolerability of AZD2927, at screening [ Time Frame: Monitoring of Adverse events, Electrocardiograms, vital signs, safety lab and ophtalmologic variables at screening ] [ Designated as safety issue: Yes ]
• Safety and tolerability of AZD2927, day 1 [ Time Frame: Monitoring of Adverse events, Electrocardiograms, vital signs, safety lab and ophtalmologic variables on day 1. ] [ Designated as safety issue: Yes ]
• Safety and tolerability of AZD2927, day 2 [ Time Frame: Monitoring of Adverse events, Electrocardiograms, vital signs and safety lab on day 2. ] [ Designated as safety issue: Yes ]
• Safety and tolerability of AZD2927, day 3 [ Time Frame: Monitoring of Adverse events, Electrocardiograms, vital signs, and safety lab on day 3. ] [ Designated as safety issue: Yes ]
• Safety and tolerability of AZD2927, at follow up [ Time Frame: Monitoring of Adverse events, Electrocardiograms, vital signs and safety lab at follow up. ] [ Designated as safety issue: Yes ]

• Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 1 [ Time Frame: Pharmacokinetic sampling will be performed day 1 ] [ Designated as safety issue: No ]
• Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 2 [ Time Frame: Pharmacokinetic sampling will be performed day 2 ] [ Designated as safety issue: No ]
• Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 3 [ Time Frame: Pharmacokinetic sampling will be performed day 3 ] [ Designated as safety issue: No ]

In this early phase study, healthy male volunteers will be randomly assigned to one dose of either AZD2927 or placebo. The objective will be to assess the Safety,Tolerability and Pharmacokinetics of AZD2927.

• Drug: AZD2927
  Single dose of AZD2927
• Drug: Placebo
  Single dose of placebo

• Experimental: 1
  Intervention: Drug: AZD2927
• Placebo Comparator: 2
  Intervention: Drug: Placebo

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures
• Healthy male subjects aged 18 to 45 years inclusive with suitable veins for cannulation or repeated venepuncture
• Male subjects should be willing to use barrier contraception ie, condoms, from the day of dosing until 3 months after dosing with the Investigational Product (IP)
• Have a body mass index (BMI) between 19.0 and 30.0 kg/m2 and weight of at least 50.0 kg and no more than 100.0 kg

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
• History or presence of gastrointestinal, mental, cardiac, hepatic or renal disorder, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• Abnormal vital signs, after 10 minutes supine rest
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of IP
• Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator